SEC Comment Letter for Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Apr 25, 2012
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: April 25, 2012 · CIK: 0001130166 · Accession: 0000000000-12-021071
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50626
Letter
April 19, 2012 Via E-mail Spiro Rombotis President and Chief Executive Officer Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 Re: Cyclacel Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on April 6, 2012 File No. 000-50626
Dear Mr. Rombotis: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director cc: Jeffrey Schultz Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 666 Third Avenue New York, NY 10017
Show Raw Text
April 19, 2012 Via E-mail Spiro Rombotis President and Chief Executive Officer Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 Re: Cyclacel Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on April 6, 2012 File No. 000-50626 Dear Mr. Rombotis: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director cc: Jeffrey Schultz Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 666 Third Avenue New York, NY 10017